Affordable Access

Access to the full text

Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation

Authors
  • Hospital, Marie Anne1
  • Vey, Norbert2
  • 1 Institut Paoli-Calmettes, Marseille, France , Marseille (France)
  • 2 Institut Paoli-Calmettes, 232 Bvd Sainte Marguerite, Marseille, 13009, France , Marseille (France)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Jan 23, 2020
Volume
22
Issue
1
Identifiers
DOI: 10.1007/s11912-020-0869-0
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of ReviewTo understand how myelodysplastic syndromes (MDS) transform to AML and to describe how transformation can be predicted and prevented.Recent FindingsRecent genomic analyses have shown that MDS progression to AML is associated with clonal expansion and clonal evolution. Mutation profiles of MDS change during progression and new mutations in signaling genes and transcription factors emerge. AML transformation can be predicted by several parameters including International Prognostic Scoring System IPSS risk category and transfusion requirements. The prognostic relevance of the acquisition of some gene mutations (i.e., IDH1 and 2, CBL, FT3, RAS, NPM1, TP53, and ASXL1) has to be prospectively validated. The most effective preventive therapy for AML transformation is allogeneic stem cell transplantation. Hypomethylating agents have been associated with prolonged time to AML transformation even in patients who did not achieve an objective response.SummaryThe recent progress in the understanding of the molecular events leading to transformation and the event of new effective therapies open new avenues for a better prediction and prevention of AML transformation in patients with MDS.

Report this publication

Statistics

Seen <100 times